Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription


1 Am J Dermatopathol
2 Ann Surg Oncol
1 Anticancer Res
2 BMC Cancer
1 BMC Ophthalmol
1 Br J Cancer
1 Cancer Lett
2 Cancer Res
1 J Immunol
1 J Invest Dermatol
2 N Engl J Med
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Dermatopathol

  1. ZABALLOS P, Lara-Valencia P, Van Den Bossche K, Sanchez-Martinez E, et al
    Clear Cell Proliferations of the Skin: A Histopathologic Review.
    Am J Dermatopathol. 2021;43:607-636.
    PubMed         Abstract available

    Ann Surg Oncol

  2. KARAKOUSIS G, Zager J
    Prognostic Biomarkers in Melanoma: The Legacy of a Surgeon Scientist Who Followed the Data.
    Ann Surg Oncol. 2022 Jan 2. pii: 10.1245/s10434-021-11273.

  3. DAVIS CH, Ho J, Greco SH, Koshenkov VP, et al
    ASO Visual Abstract: COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States.
    Ann Surg Oncol. 2022 Jan 1. pii: 10.1245/s10434-021-11179.

    Anticancer Res

    Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8(+) T Cells: A Study Based on The Cancer Genome Atlas (TCGA).
    Anticancer Res. 2022;42:511-517.
    PubMed         Abstract available

    BMC Cancer

  5. SABAZADE S, Herrspiegel C, Gill V, Stalhammar G, et al
    Correction to: No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
    BMC Cancer. 2022;22:32.

  6. KARACHALIOU GS, Alkallas R, Carroll SB, Caressi C, et al
    The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
    BMC Cancer. 2022;22:38.
    PubMed         Abstract available

    BMC Ophthalmol

  7. KROHN J, Sundal KV, Froystein T
    Topography and clinical features of iris melanoma.
    BMC Ophthalmol. 2022;22:6.
    PubMed         Abstract available

    Br J Cancer

  8. HAMIS SJ, Kapelyukh Y, McLaren A, Henderson CJ, et al
    Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Br J Cancer. 2021;125:1552-1560.
    PubMed         Abstract available

    Cancer Lett

  9. TIAN C, Liu J, Zhou H, Li J, et al
    Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Cancer Lett. 2021;518:49-58.
    PubMed         Abstract available

    Cancer Res

  10. XU F, Wang Z, Zhang H, Chen J, et al
    Mevalonate Blockade in Cancer Cells Triggers CLEC9A(+) Dendritic Cell-Mediated Antitumor Immunity.
    Cancer Res. 2021;81:4514-4528.
    PubMed         Abstract available

  11. LIU H, Yang J, Zhang Y, Han J, et al
    Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1alpha Signaling.
    Cancer Res. 2021;81:5353-5365.
    PubMed         Abstract available

    J Immunol

  12. BANERJEE A, Li D, Guo Y, Mahgoub B, et al
    Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy.
    J Immunol. 2021;207:333-343.
    PubMed         Abstract available

    J Invest Dermatol

  13. BECHMANN N, Calsina B, Richter S, Pietzsch J, et al
    Therapeutic Potential of Nitric Oxide releasing Selective Estrogen Receptor Modulators (NO-SERMs) in Malignant Melanoma.
    J Invest Dermatol. 2022 Jan 3. pii: S0022-202X(21)02691.
    PubMed         Abstract available

    N Engl J Med

  14. FRAMPTON AE, Sivakumar S
    A New Combination Immunotherapy in Advanced Melanoma.
    N Engl J Med. 2022;386:91-92.

  15. TAWBI HA, Schadendorf D, Lipson EJ, Ascierto PA, et al
    Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    N Engl J Med. 2022;386:24-34.
    PubMed         Abstract available

    PLoS One

  16. BRASSARD J, Gill ME, Bernatchez E, Desjardins V, et al
    Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy.
    PLoS One. 2021;16:e0260636.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.